Axsome Therapeutics (AXSM) Tops Q1 EPS by $1.03; Offers Operational Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
May 8, 2023 7:00 AM EDTAuvelity® 1Q 2023 net product sales of $15.7 million
Total 1Q 2023 net product sales of $28.6 million
Total 1Q 2023 revenue of $94.6 million, including Sunosi® ex-U.S. license agreement upfront payment
Company to host conference call today at 8:00 AM Eastern
NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported... More
